title: Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma.
abstract: Poly(C)‑binding protein 2 (PCBP2) is a member of the PCBP family, and plays an important role in post‑transcriptional and translational regulation of various signaling molecules through direct binding to single‑stranded poly(C) motifs. PCBP2 has been reported to play a critical role in the development of multiple human tumors. However, whether PCBP2 participates in hepatocellular carcinoma (HCC) development remains largely elusive. Herein, we showed that PCBP2 was upregulated in human HCC tissues and cell lines. Overexpression of PCBP2 predicted significantly worsened prognosis in HCC patients, suggesting that PCBP2 may serve as a prognostic marker of HCC. In addition, we found that depletion of PCBP2 inhibited HCC cell proliferation, accompanying the increase in the cyclin‑dependent kinase inhibitor p27 level. Moreover, we found that high expression of PCBP2 may contribute to sorafenib resistance in HCC cells, involving dysregulated expression of Bax and Bcl‑2 proteins. In conclusion, our results suggest that PCBP2 may serve as a prognostic marker and potential therapeutic target of HCC.
authors.affiliation: Department of Oncology, Nantong Second People's Hospital, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Xiubing
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Jiangsu Province Key Laboratory for Inﬂammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Lu
authors.initials: L
authors.lastname: Hua
authors.affiliation: Jiangsu Province Key Laboratory for Inﬂammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Daliang
authors.initials: D
authors.lastname: Yan
authors.affiliation: Basic Medical Research Centre, Medical College, Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Fengbo
authors.initials: F
authors.lastname: Zhao
authors.affiliation: Jiangsu Province Key Laboratory for Inﬂammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Jinxia
authors.initials: J
authors.lastname: Liu
authors.affiliation: Jiangsu Province Key Laboratory for Inﬂammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Huiling
authors.initials: H
authors.lastname: Zhou
authors.affiliation: Jiangsu Province Key Laboratory for Inﬂammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.affiliation: Jiangsu Province Key Laboratory for Inﬂammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Miaomiao
authors.initials: M
authors.lastname: Wu
authors.affiliation: Jiangsu Province Key Laboratory for Inﬂammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Chengliang
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Jiangsu Province Key Laboratory for Inﬂammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Yingying
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Radiotherapy, Afﬁliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Buyou
authors.initials: B
authors.lastname: Chen
authors.affiliation: Basic Medical Research Centre, Medical College, Nantong University, Nantong, Jiangsu 226001, P.R. China.
authors.forename: Baoying
authors.initials: B
authors.lastname: Hu
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D019008:Drug Resistance, Neoplasm; D005260:Female; D015870:Gene Expression; D006801:Humans; D020128:Inhibitory Concentration 50; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000494:pharmacology; D011379:Prognosis; D016601:RNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D000077157:Sorafenib; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; C501903:PCBP2 protein, human; D010671:Phenylurea Compounds; D016601:RNA-Binding Proteins; D009536:Niacinamide; D000077157:Sorafenib